Timely use of Novartis' Entresto could prevent or postpone over 28,000 US deaths per year among HFrEF patients, according to an expert analysis in JAMA Cardiology

Timely use of Novartis' Entresto could prevent or postpone over 28,000 US deaths per year among HFrEF patients, according to an expert analysis in JAMA Cardiology

Jun 22, 2016
Source URL: https://qa1.novartis.us/us-en/news/media-releases/timely-use-novartis-entresto-could-prevent-or-postpone-over-28000-us-deaths-year-among-hfref-patients-according-expert-analysis-jama-cardiology-0

List of links present in page
  1. https://qa1.novartis.us/us-en/us-en/news/media-releases/timely-use-novartis-entresto-could-prevent-or-postpone-over-28000-us-deaths-year-among-hfref-patients-according-expert-analysis-jama-cardiology-0